These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9643779)

  • 41. Social cognitive predictors of intention to test for variant Creutzfeldt-Jakob disease in those affected by haemophilia and other clotting disorders.
    Rowland G; Robinson G; Chilcot J; Troop NA
    J Health Psychol; 2014 Jun; 19(6):809-17. PubMed ID: 23520351
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
    Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
    N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modern treatment of hemophilia: from the shadows towards the light.
    Mannucci PM
    Thromb Haemost; 1993 Jul; 70(1):17-23. PubMed ID: 8236096
    [No Abstract]   [Full Text] [Related]  

  • 44. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.
    Darby SC; Ewart DW; Giangrande PL; Spooner RJ; Rizza CR; Dusheiko GM; Lee CA; Ludlam CA; Preston FE
    Lancet; 1997 Nov; 350(9089):1425-31. PubMed ID: 9371165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Who should be liable for funding recombinant factor VIII?
    Richards RG
    BMJ; 1998 May; 316(7141):1385-6. PubMed ID: 9564004
    [No Abstract]   [Full Text] [Related]  

  • 46. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
    van der Bom JG; Gouw SC; Rosendaal FR
    Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of haemophilia patients in East Germany prior to and after reunification in 1990.
    Lenk H
    Thromb Res; 2014 Nov; 134 Suppl 1():S57-60. PubMed ID: 24745720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 49. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful management of refractory haematuria with recombinant porcine factor VIII replacement for paediatric congenital haemophilia A with high-titre inhibitor.
    Jain S; Gupta S; Ambrusko SJ; Shapiro A
    Haemophilia; 2017 Jul; 23(4):e358-e361. PubMed ID: 28474428
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haemophilia and AIDS.
    Bird AG; Codd AA; Collins A
    Lancet; 1985 Jan; 1(8421):162-3. PubMed ID: 2857233
    [No Abstract]   [Full Text] [Related]  

  • 53. An outbreak of hepatitis A among Irish haemophiliacs.
    Johnson Z; Thornton L; Tobin A; Lawlor E; Power J; Hillary I; Temperley I
    Int J Epidemiol; 1995 Aug; 24(4):821-8. PubMed ID: 8550281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products.
    Millar CM; Makris M
    Br J Haematol; 2012 Aug; 158(4):442-52. PubMed ID: 22775486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection].
    Siegmund B; Pollmann H; Richter H; Orlovic M; Gottstein S; Klamroth R
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S37-9. PubMed ID: 21042673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom.
    Rizza CR; Spooner RJ
    Br Med J (Clin Res Ed); 1983 Mar; 286(6369):929-33. PubMed ID: 6403138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pioneering therapeutic proteins in hemophilia care through innovative technologies.
    Pabinger-Fasching I; Négrier C
    Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062
    [No Abstract]   [Full Text] [Related]  

  • 60. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.